4870-16-0

Basic information

• Product Name: 2-Anilino-2H-isoindole-1,3-dione
• Synonyms: 2-(Phenylamino)-2H-isoindole-1,3-dione;2-Anilino-2H-isoindole-1,3-dione;N-(Phenylamino)phthalimide
• CAS NO: 4870-16-0
• Molecular Formula: C₁₄H₁₀N₂O₂
• Molecular Weight: 238.2414
• Mol File: 4870-16-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 183-184 °C
• Boiling Point: 405.4°Cat760mmHg
• Flash Point: 199°C
• Appearance: /
• Density: 1.422g/cm³
• Vapor Pressure: 8.8E-07mmHg at 25°C
• Refractive Index: 1.73
• PKA: 0.39±0.20(Predicted)
• CAS DataBase Reference: 2-Anilino-2H-isoindole-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Anilino-2H-isoindole-1,3-dione(4870-16-0)
• EPA Substance Registry System: 2-Anilino-2H-isoindole-1,3-dione(4870-16-0)

Safety Data

• Hazardous Substances Data: 4870-16-0(Hazardous Substances Data)

Usage

General Description

2-Anilino-2H-isoindole-1,3-dione, also known as isatin, is a heterocyclic compound with a unique structure of a fused isoindole and indole ring system. It is a yellowish-white solid with a melting point of around 200°C, and is sparingly soluble in water but more soluble in organic solvents. Isatin is widely used in the pharmaceutical industry as a building block for the synthesis of various biologically active compounds, particularly for the development of potential anti-cancer, anti-bacterial, and anti-inflammatory drugs. It also has applications in the fields of dyes and pigments, as well as in the study of organic reactions and mechanisms in chemistry. Isatin has also shown potential for use as a reversible inhibitor of monoamine oxidase, an enzyme associated with various neurological disorders, making it a promising compound for medical research and drug development.

InChI:InChI=1/C14H10N2O2/c17-13-11-8-4-5-9-12(11)14(18)16(13)15-10-6-2-1-3-7-10/h1-9,15H

Upstream product

• 85-44-9 phthalic anhydride 
• 64-17-5 ethanol 
• 100-63-0 phenylhydrazine 
• 70454-43-2 2',2'-diphenyl-1,2-benzene-dicarboxylic acid dihydrazide 
• 6365-50-0 [2]quinolylmethylene-phthalide 
• 64-19-7 acetic acid 
• 59-88-1 phenylhydrazine hydrochloride 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 7706-75-4 2-(3-oxo-3H-isobenzofuran-1-ylidene)-1-phenyl-butane-1,3-dione 
• 7647-01-0 hydrogenchloride 
• 7732-18-5 water 
• 136918-14-4 phthalimide 
• 50930-79-5 anilinophthalamic acid 
• 524-38-9 N-hydroxyphthalimide 

Downstream Products

• 136918-14-4 phthalimide 
• 92-67-1 4-phenylalanine 
• 90-41-5 2-phenylaniline 
• 122-39-4 diphenylamine 
• 5439-98-5 4-hydroxy-2-phenylphthalazin-1(2H)-one 
• 6295-93-8 2-(diphenylamino)isoindoline-1,3-dione 
• 29110-76-7 2-[(2-phenylhydrazino)carbonyl]benzoic acid 
• 100-63-0 phenylhydrazine 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 520-03-6 N-phenylphthalimide 
• 7664-41-7 ammonia 
• 1073950-92-1 methyl (2-anilino-3-oxo-2,3-dihydro-1H-isoindol-1-yl)acetate 
• 1372401-30-3 ethyl 2-(2-(phenylamino)-3-oxoisoindol-1-yl)acetate 
• 1372401-32-5 C₁₈H₁₇N₂O₃^(1-)*K⁽¹⁺⁾ 

Relevant articles and documents

2-Phenyl-4-hydroxyphthalazin-1-one: A Benzoannelated Derivative of Maleic Hydrazide

The monoclinic crystals (space group P21/a, Z = 8) of 2-phenyl-4-hydroxyphthalazin-1-one. C14H10N2O2, have two independent molecules (A and B) in the asymmetric unit. Both occur as the lactim-lactam (hydroxy-one) structure, which is also found in the parent molecule maleic hydrazide (both triclinic and monoclinic polymorphs), dichloromaleic hydrazide and luminol (3-aminophthalhydrazide). The molecular arrangement is based on strings of alternating A and B molecules linked by hydroxyl...carbonyl hydrogen bonds, with only van der Waals interactions between adjacent strings. Comparison is made of the measured bond lengths for (monoclinic) maleic hydrazide and values from high-level ab initio calculations, and reasonably good agreement is obtained, with indications of improvements when allowance is made for electron correlation and hydrogen bonding.

INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS

This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers. This disclosure also relates to compositions comprising inhibitors of IRES-mediated protein synthesis and mTOR inhibitors, and to methods of treating cancer by conjoint administration of inhibitors of IRES-mediated protein synthesis and mTOR inhibitors.

Using of 4-(4′-methylbenzylidene)-1-hydroxy-2-(n-phthalimidomethyl) - 5 - Imidazolone as a building block in synthesis of some heterocyclic compounds

-